Last updated: February 27, 2026
What is the drug associated with NDC 00527-4579?
NDC 00527-4579 refers to Ozempic (semaglutide) injection, 1 mg. Ozempic is a GLP-1 receptor agonist used for managing type 2 diabetes. Its indications include glycemic control and, in some territories, weight management.
What is the current market landscape for semaglutide-based therapies?
Semaglutide, marketed primarily as Ozempic, has seen rapid growth due to high efficacy and favorable safety profiles. It competes with other GLP-1 receptor agonists like liraglutide (Victoza), dulaglutide (Trulicity), and exenatide (Bydureon).
Over 2022–2023:
- Global sales of Ozempic exceeded $6 billion annually.
- Usage is rising due to multiple approvals, including Europe and the U.S. for weight loss under Wegovy (higher-dose semaglutide).
- Growth is driven by expanding indications, patient demand, and increasing physician adoption.
What are the key drivers influencing market growth?
- Expanding Indications: Diabetes management, obesity treatment, cardiovascular risk reduction.
- Pricing and Reimbursement: Well-reimbursed in major markets; price premiums for new indications.
- Physician and Patient Adoption: Increasing awareness and comfort with injectable drugs.
- Manufacturing Capacity: Novo Nordisk, the manufacturer, has expanded production; expects to meet rising demand.
What are the current pricing benchmarks?
U.S. Pricing (2023):
- List Price: Approximately $1,350 per 4 mg/0.5 mL injection.
- Average Wholesale Price (AWP): $1,200–$1,300, before discounts.
- Insurance and Pharmacy Benefit Manager (PBM) negotiated prices: Significantly lower, often around 20–30% discount.
International Pricing:
- Countries like Canada and European nations implement price negotiations leading to prices 40–50% lower than U.S. list prices.
- Tiered pricing models are present in emerging markets.
How is the market expected to evolve?
| Year |
Estimated Global Sales |
Key Drivers |
Commentary |
| 2023 |
$6.5 billion |
Market maturity, expanded indications |
Continued growth expected; nearing saturation in some markets |
| 2024 |
$8.2 billion |
New markets, broader indication utilization |
Growth driven by obesity indication approvals and increased patient access |
| 2025 |
$10.5 billion |
Competitive entrants, fixed-dose formulations |
Market penetration deepens, price erosion begins but volume growth sustains |
What are the price projections?
Based on current trends:
- Short-term (2024): Price stability or slight decline (~5–10%) due to increased competition and biosimilars.
- Mid-term (2025): Price could decline further (~10–15%) as biosimilars or alternative therapies enter the market.
- Long-term (2026+): Price stabilization likely at a 20–30% discount from 2023 levels, sustained by a broadening treatment landscape.
What regulatory factors impact pricing?
- Pricing negotiations: Governments and payers influence list prices via reimbursement negotiations.
- Patent status: Patent exclusivity protects pricing; patent expirations or legal challenges could introduce biosimilar competition.
- Pricing legislation: Countries implementing tighter controls on drug prices can accelerate price reductions.
Summary
NDC 00527-4579 corresponds to Ozempic, a major player in the GLP-1 class. The market will grow driven by indication expansion and increasing patient access. Price projections suggest moderate downward adjustments, with sustained high-volume sales.
Key Takeaways
- Ozempic dominates the GLP-1 market with sales exceeding $6 billion in 2022.
- Pricing is approximately $1,350 per 4 mg pre-discount in the U.S.
- Market growth is projected to reach over $10 billion globally by 2025.
- Price declines of 10–15% expected in the next 2 years as biosimilars and competition emerge.
- Regulatory and reimbursement environments heavily influence future pricing trends.
FAQs
What factors could accelerate price declines for Ozempic?
Introduction of biosimilars once patents expire, increased competition from alternative therapies, and stricter governmental price controls.
How might new indications influence pricing?
Additional approved uses, such as weight management, could sustain or increase prices due to premium pricing strategies for broader applicability.
Are biosimilars expected to impact the Ozempic market?
Yes. Biosimilar entrants are expected within 4–6 years, likely reducing prices by 30–50% depending on market adoption and regulatory approval.
What countries are most influential in setting global prices?
The U.S. drives revenue figures; European markets follow, often with lower prices due to centralized negotiations. Emerging markets follow with lower price points.
How does the competitive landscape influence future market share?
Presence of new GLP-1 or oral therapies can erode market share, but Ozempic's established position and expanding indications maintain its competitiveness.
Citations
[1] IQVIA. (2023). The IQVIA Institute report on global diabetes treatments.
[2] Novo Nordisk A/S annual report. (2022).
[3] U.S. Agency for Healthcare Research and Quality. (2023). Prescription Drug Price Reports.
[4] European Medicines Agency. (2023). Product information for Ozempic.
[5] EvaluatePharma. (2023). Market forecasts for GLP-1 receptor agonists.
